Xuebijing injection (XBJ) showed proven efficacy in the EXIT-SEP trial (NCT03238742), lowering 28-day mortality. However, its real-world effectiveness requires validation due to the trial's strict criteria. Broader clinical evaluation is imperative.
Hospitalized patients aged ≥18 years
Sepsis diagnosis meeting Sepsis-3 criteria
Informed consent signed by patient or legally authorized representative
Patients with a prior history of sepsis
Sepsis diagnosis >48 hours prior to enrollment
Current participation in clinical trial